Occupational coal tar dermatitis

L. Condé‐Salazar,D. Guimaraens,L. Romero,M. Gonzalez

DOI: https://doi.org/10.1111/J.1600-0536.1987.TB01436.X

1987-04-01

Contact Dermatitis

Abstract:

What problem does this paper attempt to address?

[Pharmacovigilance guidelines of Chinese patent medicines]

Lian-Xin Wang,Meng-Meng Wang,Yuan-Yuan Li,Zhi-Fei Wang,Xin Cui,Xiao-Xiao Zhao,Fu-Mei Liu,Shuo Yang,Rui-Li Wei,Ya-Xing Wang,Bing Zhang,Yan-Ming Xie

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20240623.501

Abstract:Drug administration law of the People's Republic of China(2019 revised edition), which came into effect on December 1, 2019, proposed that " the state shall establish a pharmacovigilance system". Pharmacovigilance work of Chinese patent medicines is more difficult, and it is necessary to carry out Pharmacovigilance activities that are in line with the characteristics of Chinese patent medicines. Pharmacovigilance guidelines of Chinese patent medicines(T/CACM 1563. 1-2024), based on the principles of Drug Administration Law of the People's Republic of China(2019 revised edition) and Pharmacovigilance quality management standards(No. 65 of 2021) of the National Medical Products Administration, draws on the EU Pharmacovigilance regulation and the secondary guidelines of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH), and it is drafted in accordance with the provisions of Guidelines for standardization work part 1: structure and drafting rules of standardization documents(GB/T1. 1-2020) based on the characteristics of Chinese patent medicines. It serves as a general document for a series of pharmacovigilance guidelines of Chinese patent medicines, such as Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions(T/CACM 1563. 2-2024), Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines(T/CACM 1563. 3-2024), Pharmacovigilance guidelines for clinical application of traditional Chinese medicine injections(T/CACM 1563. 4-2024), Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use(T/CACM 1563. 5-2024), and Pharmacovigilance guidelines for clinical application of Chinese patent medicines for mucosal administration(T/CACM 1563. 6-2024), including four major elements of pharmacovigilance monitoring and reporting of Chinese patent medicines, signal identification, risk evaluation, and risk control, as well as pharmacovigilance activities for Chinese patent medicines, ensuring the safety of public drug use.
[Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines]

Lian-Xin Wang,Shuo Yang,Rui-Li Wei,Yuan-Yuan Li,Xin Cui,Xiao-Xiao Zhao,Wen-Xi Peng,Fu-Mei Liu,Meng-Meng Wang,Xiu-Hui Li,Zhi-Fei Wang,Yan-Ming Xie

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20240517.501

Abstract:Oral Chinese patent medicine is the essence of effective prescriptions created and summarized by Chinese medical scientists through thousands of years of medical practice. It is portable and convenient, with an obvious curative effect and other characteristics. However, at present, oral Chinese patent medicine is rich in dosage forms, various in types, complex in mechanism of action, and broad in clinical positioning. In clinical application, there are often cases of drug use without reference to instructions,repeated drug use, and prolonged drug use, which highlights safety problems such as adverse reactions and hepatorenal toxicity. Oral Chinese patent medicine pharmacovigilance is facing challenges. World Health Organization(WHO) has issued the WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH) has issued the ICH E2 pharmacovigilance guidelines. The United States has issued the Pharmacovigilance management standards and pharmacoepidemiological assessment guidelines, and the European Union has issued the Guidelines on good pharmacovigilance practices. Japan, South Korea, and other countries in the Asia Pacific region have established their own pharmacovigilance systems, but currently, there are no pharmacovigilance guidelines related to oral Chinese patent medicine in China. Therefore, experts from many disciplines and fields in China were invited to jointly develop the Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines, which aims to develop pharmacovigilance guidelines for clinical application that are consistent with China's national conditions and highlight the characteristics of oral Chinese patent medicine, and provide guidance for clinically safe and rational drug application in medical institutions.
[Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use]

Xin Cui,Ding-Quan Yang,Zhen-Nian Xie,Yuan-Yuan Li,Zhi-Fei Wang,Huan Liu,Fu-Mei Liu,Xiao-Xiao Zhao,Zhen-Kai Lu,Lian-Xin Wang,Yan-Ming Xie

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20240621.501

Abstract:There are many kinds and dosage forms of Chinese patent medicines for external use on the market, which are widely used in clinical departments. The common adverse reactions of Chinese patent medicines for external use are skin reactions, and those for the rare severe diseases include palpitation, chest tightness, dyspnea, and anaphylactic shock. At present, World Health Organization(WHO), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH),the United States, the European Union, and Asia-Pacific countries(such as Japan and South Korea) have not issued any pharmacovigilance guideline of Chinese patent medicines for external use. China has not issued any pharmacovigilance guideline for these medicines, only releasing the standard Evaluation of skin adverse reactions caused by Chinese patent medicines for external use(T/CACM 005-2017). To standardize the safe and reasonable use of Chinese patent medicines for external use, Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use was developed with the joint efforts of experts in diverse disciplines. The guideline provides guidance on the monitoring and reporting of adverse reactions/events, identification and assessment of risk signals, and risk control measures in the clinical application of Chinese patent medicines for external use to guide the rational use of these medicines in clinical practice. At the same time, the possible risks and risk control measures in clinical application of Chinese patent medicines for external use are listed for clinical reference. In addition, the guideline provides guidance for risk minimization plans and the standardization of activities related to pharmacovigilance of Chinese patent medicines for external use in China.
[Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions]

Fu-Mei Liu,Li Zhang,Yuan-Yuan Li,Zhi-Fei Wang,Xiao-Xiao Zhao,Xin Cui,Rui-Li Wei,Shuo Yang,Lian-Xin Wang,Yan-Ming Xie

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20240509.501

Abstract:The group standard Guidelines for construction of traditional Chinese medicine(TCM) pharmacovigilance system in medical institutions, managed by Chinese Association of Chinese Medicine and led by the Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences and Dongfang Hospital of Beijing University of Chinese Medicine, was announced on National Group Standard Information Platform on January 16, 2024, with the standard number T/CACM 1563. 2-2024. According to EU pharmacovigilance regulations and the second-level guidance principles of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH), the unique characteristics of TCM were fully considered, and the relevant systems and procedures for constructing TCM pharmacovigilance systems in medical institutions were clearly defined. This included establishing TCM pharmacovigilance information platforms, arranging staff, formulating various regulations, and monitoring adverse reactions of TCM(including TCM decoction pieces, granules, Chinese patent medicines, in-hospital preparations, and pre-marketed Chinese patent medicines). It aimed to develop a TCM pharmacovigilance system in medical institutions that was tailored to the characteristics of TCM. The system could be appropriately adjusted according to the scope of practice and actual circumstances of medical institutions at different levels. This will enhance the implementation of TCM pharmacovigilance work and safeguard medication safety. The group standard underwent multiple rounds of consultations with internal and external experts and has ultimately evolved into a guiding document applicable to medical institutions and related entities engaged in pharmacovigilance activities.
Beyond freedom and dignity at 40: Comments on behavioral science, the future, and chance (2007)

S. Leigland

DOI: https://doi.org/10.1007/BF03392258

The Behavior Analyst

Abstract:
Notice for Western Medicine Physicians in Clinical Use of Chinese Patent Drugs

XU Xiaoyan,ZHOU Jun

DOI: https://doi.org/10.3969/j.issn.1001-0408.2007.36.034

2007-01-01

Abstract:OBJECTIVE:To offer references for clinical rational use of Chinese patent drugs. METHODS:The basic theory of Chinese medicine was applied to analyze the current common problems encountered by western medicine physicians in the use of Chinese patent drugs. RESULTS CONCLUSION:In the clinical use of Chinese patent drugs, the western medicine physicians should give consideration of the specific condition and get a detailed knowledge of drug constituents and the related clinical data as well as strictly follow the specification of drug package inserts.
Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine

Yan-ming XIE,Xing LIAO,Jun-jie JIANG,Yun-ling ZHANG,Rong MA,Ming-jun ZHU,Si-yan ZHAN,Jian-ping LIU,Jian LIU,Ze-huai WEN,Zhong-qi YANG,Yan HE,Xue-lin LI

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20190509.504

2019-01-01

Abstract:In 2013,China pharmaceutical regulatory department issued guiduance on postmarketing drug safety monitoring for industry. It aimed to encourage industry to carry out postmarketing drug safety monitoring including hospital-based intensive monitoring of postmarketing Chinese patent medicine. Subsequently,more and more such kind of studies have been performed all over China. However,in view of the current situation in this field,the development of hospital-based intensive monitoring of postmarketing Chinese patent medicine lacks standardization,such as unreasonable design,omission of reports about adverse drug reactions,inadequate process of quality control,non-standardized interpretation of adverse reactions,etc. Therefore,it is necessary to formulate relevant technical specifications to guide this area. The developing of this technical specification refered to the international post-marketing safety monitoring model and advanced design concepts and methods. We developed it under the guidance of relevant laws,regulations and technical documents in China. Meanwhile the characteristics of Chinese patent medicines and the real situation in this area were considered. The aim of this technical specification is to obtain the incidence,type,degree and clinical manifestation of adverse drug reactions of Chinese patent medicines,to find new risk signals of adverse reactions,to identify risk factors,and to provide a basis for the formulation of risk management and control plans. This specification has been approved by China association of Chinese medicine which is numbered T/CACM011-2016.
[Report standards for clinical comprehensive evaluation of Chinese patent medicine]

Qiang Zhang,Zhi-Fei Wang,Yan-Ming Xie,Yuan-Yuan Li,Lian-Xin Wang,Huan Liu,Hong-Jiao Geng,Xin Cui,Fu-Mei Liu,Chun-Quan Sun,Rui-Li Wei,Li-Dan Zhang

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20210930.502

Abstract:The clinical comprehensive evaluation of drugs is an important basis for the return of clinical value, decision-making of medical and health authorities, and allocation of medical resources. In July 2021, the National Health Commission issued the Guidelines for the Management of Clinical Comprehensive Evaluation of Drugs(trial version 2021), which required the evaluation to be implemented from the six dimensions(safety, effectiveness, economy, innovation, suitability, and accessibility), and made detailed arrangements for the clinical comprehensive evaluation of drugs. As Chinese patent medicine differs from chemical medicines in terms of effective components and action modes, the clinical comprehensive evaluation of Chinese patent medicine should highlight the characteristics and advantages of traditional Chinese medicine(TCM) on the basis of general requirements of comprehensive clinical evaluation of drugs. At present, in the clinical comprehensive evaluation of Chinese patent medicine, unified report standards have not yet been generated, resulting in the uneven quality of existing reports. To standardize the clinical comprehensive evaluation report of Chinese patent medicine and improve its quality, the editorial team, based on the relevant policy documents of clinical comprehensive evaluation of drugs, formulated the clinical comprehensive evaluation report standards for Chinese patent medicine in combination with the previous practice and expert opinions. The report standards, containing seven sections with 15 items determined, focus on data source, evaluation content, evidence synthesis, quality control, and evaluation results supported with detailed interpretations to help researchers better understand and apply the report standards for clinical comprehensive evaluation of Chinese patent medicine, improve the report quality, and provide references for the decision-making by the national medical management authorities.
An Intelligent Information Dictionary for Semantic Manipulation of Relational Databases

Stephanie J. Cammarata

DOI: https://doi.org/10.1007/3-540-19074-0_55

1988-03-14

Abstract:
Clinical practice guidelines of Chinese patent medicine in China: A critical review

Jian-Xin Wang,Rui Sun,Dong-Xu Si,Man-Ping Guo,Lijing Zhang,Yuan-Yuan Sun,Xue-Min Gao,Rui Gao

DOI: https://doi.org/10.1016/j.ctim.2024.103077

2024-08-23

Abstract:Objectives: To analyze the methodology, evidence, recommendations, quality, and implementation of traditional Chinese patent medicine (CPM) guidelines. Methods: We retrieved clinical application guidelines of CPM published from 2019 to 2022. Independent screening and data extraction were performed by two evaluators. The basic information about the guidelines, including evidence and recommendations, were extracted and statistically analyzed. Quality and implementation were evaluated using the Implementation Evaluation Tool and Appraisal of Guidelines for Research & Evaluation (AGREE) II. Results: In total, 29 guidelines were analyzed, including 262 recommendations and 2308 references. All the CPM guidelines followed the principle of "evidence as a core, consensus as a supplement, and experience as a reference" and the methods provided by WHO Handbook. An average of 89 references were cited in each guideline and 8 in each recommendation. Randomized controlled trials and systematic reviews constituted 89 % and 0.9 %, respectively, of all references. Low or very low-quality evidence characterized 74.5 % and weak recommendations characterized 83.6 %. Of all recommendations, 13.7 % were based on expert consensus, and 9.5 % of strong recommendations were based on low or very low-quality evidence. The AGREE II scores for each domain were: scope and purpose (79.63 %) and editorial independence (79.27 %), followed by clarity of presentation (72.59 %), stakeholder involvement (69.99 %), rigor of development (53.97 %) and applicability (5.11 %). The implementation quality of most guidelines was either high (44.8 %) or moderate (55.2 %). Conclusions: The results for CPM guidelines were impressive in terms of methodology, quality, and implementation. However, confidence in CPM recommendations was downgraded by low quality of evidence.
Recent advances in Chinese patent medicines entering the international market

Bo Zhang,Wenjian Pei,Pingping Cai,Zhixue Wang,Fanghua Qi

DOI: https://doi.org/10.5582/ddt.2022.01115

2022-12-25

Drug Discoveries & Therapeutics

Abstract:As an indispensable part of Traditional Chinese medicine (TCM), Chinese patent medicines have played an important role in preventing and treating diseases in China. Since they are easy to use, easy to store, and cost-effective, Chinese patent medicines have been generally accepted and widely used in Chinese clinical practice as a vital medical resource. In recent years, as TCM has developed and it has been accepted around the world, many Chinese patent medicine companies have gained international market access and successfully registered several Chinese patent medicines as over-the-counter (OTC) or prescription drugs in regions and countries that primarily use Western medicine such as the EU, Russia, Canada, Singapore, and Vietnam. Moreover, several Chinese patent medicines have been obtained the US Food and Drug Administration (FDA) approval conducting phase II or III clinical trials in the US. The current work has focused on several Chinese patent medicines that have been successfully registered or that have been submitted for registration abroad. Summarized here are recent advances in the efficacy and molecular mechanisms of these Chinese patent medicines to treat respiratory infectious diseases (Lianhua Qingwen capsules, Jinhua Qinggan granules, and Shufeng Jiedu Capsules), cardiovascular and cerebrovascular diseases (Compound Danshen Dripping Pills, Huatuo Zaizao pills, and Tongxinluo Capsules), cancers (a Kanglaite injection and a Shenqi Fuzheng Injection), and gynecological diseases (Guizhi Fuling Capsules). The hope is that this review will contribute to a better understanding of Chinese patent medicines by people around the world.
Answer to case of the month #136. Endometrioma of the rectus sheath after Caesarean section.

J. Feeney,P. Govender,A. Snow,W. Torreggiani

2008-10-01

Abstract:
[On the possibilities of prevention of afibrinogenemic hemorrhages].

A. Grigorian

Abstract:
Pharmacovigilance in China: A review

Haibo Song,Xiaojing Pei,Zuoxiang Liu,Chuanyong Shen,Jun Sun,Yuqin Liu,Lingyun Zhou,Sun Feng,Xiaohe Xiao

DOI: https://doi.org/10.22541/au.163483847.79222435/v1

2021-01-01

Abstract:Drug-related adverse reactions are among the main reasons for harm to patients under care worldwide and even their deaths. The pharmacovigilance system has been proven to be an effective method of avoiding or alleviating such adverse events. In 2019, after two decades of implementation of the drug-related adverse reaction reporting system, China formally implemented a pharmacovigilance system with the Pharmacovigilance Quality Management Standards and a series of supporting technical documents created to improve the safety of medication given to patients. China’s pharmacovigilance system has faced many problems and challenges during its implementation. This spontaneous reporting system is the main source of data for China’s medication vigilance activities, but it has not provided sufficiently powerful evidence for regulatory decision-making. In conformity to the health-centered drug regulatory concept, the Chinese government has accelerated the speed of examination and approval of urgently needed clinical drugs and orphan drugs along with the requirement to improve the safety supervision of these drugs after their listing. China’s marketing authorization holders（MAHs）must strengthen its pharmacovigilance capabilities as the primary responsible department for drug safety. Chinese medical schools generally lack professional courses on pharmacovigilance. The regulatory authorities have recognized such problems and have made efforts to improve the professional capacity of pharmacovigilance personnel and to strengthen cooperation with stakeholders through the implementation of an action plan of medication surveillance and the establishment of patient-based adverse events reporting system and active surveillance systems, which will help China bridge the gap to bring its pharmacovigilance practice up to standards.
Guideline on treating community-acquired pneumonia with Chinese patent medicines

Minghang Wang,Huiguo Liu,Yaolong Chen,Jiajie Yu,Jiangtao Lin,Zengtao Sun,Jiansheng Li,Gang Bai,Fuqiang Wen,Yang Xie,Jianxin Wang,Jiang Yang,Suyun Li

DOI: https://doi.org/10.1016/j.phrs.2023.106919

IF: 10.334

2023-10-01

Pharmacological Research

Abstract:Community-acquired pneumonia (CAP) is one of the most common infectious diseases, and its morbidity and mortality increase with age. Resistance and mutations development make the use of anti-infective therapy challenging. Chinese patent medicines (CPMs) are often used to treat CAP in China and well tolerable. However, currently there are no evidence-based guideline for the treatment of CAP with CPMs, and the misuse of CPMs is common. Therefore, we established a guideline panel to develop this guideline. We identified six clinical questions through two rounds of survey, and we then systematically searched relevant evidence and performed meta-analyses, evidence summaries and GRADE decision tables to draft recommendations, which were then voted on by a consensus panel using the Delphi method. Finally, we developed ten recommendations based on evidence synthesis and expert consensus. For the treatment of severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Xuebijing injection, Shenfu injection, and Shenmai injection respectively. For the treatment of non-severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Lianhua Qingwen capsule/granule, Qingfei Xiaoyan Pill and Shufeng Jiedu capsule respectively. CPMs have great potential to help in the fight against CAP worldwide, but more high-quality studies are still needed to strengthen the evidence.

pharmacology & pharmacy
Pharmacovigilance in China: Evolution and future challenges.

Haibo Song,Xiaojing Pei,Zuoxiang Liu,Chuanyong Shen,Jun Sun,Yuqin Liu,Lingyun Zhou,Feng Sun,Xiaohe Xiao

DOI: https://doi.org/10.1111/bcp.15277

2023-01-01

British Journal of Clinical Pharmacology

Abstract:Drug-related adverse reactions are among the main reasons for harm to patients under care worldwide and even their deaths. The pharmacovigilance system has been proven to be an effective method of avoiding or alleviating such adverse events. In 2019, after two decades of implementation of the drug-related adverse reaction reporting system, China formally implemented a pharmacovigilance system with the Pharmacovigilance Quality Management Standards and a series of supporting technical documents created to improve the safety of medication given to patients. China's pharmacovigilance system has faced many problems and challenges during its implementation. This spontaneous reporting system is the main source of data for China's medication vigilance activities, but it has not provided sufficiently powerful evidence for regulatory decision-making. In conformity with the health-centred drug regulatory concept, the Chinese government has accelerated the speed of examination and approval of urgently needed clinical drugs and orphan drugs along with the requirement to improve the safety supervision of these drugs after their listing. China's marketing authorization holders (MAHs) must strengthen their pharmacovigilance capabilities as the primary responsible departments for drug safety. Chinese medical schools generally lack professional courses on pharmacovigilance. The regulatory authorities have recognized such problems and have made efforts to improve the professional capacity of pharmacovigilance personnel and to strengthen cooperation with stakeholders through the implementation of an action plan of medication surveillance and the establishment of a patient-based adverse events reporting system and active surveillance systems, which will help China bridge the gap to bring its pharmacovigilance practice up to standards.
Clinical application of oral Chinese Patent Medicines in ophthalmology: a scoping review protocol

Kai Xu,Xing Liao,Lina Liang,Yamin Li,Ziyang Huang,Xiaoyu Li,Wei Zhou,Qianqian Zuo

DOI: https://doi.org/10.1136/bmjopen-2021-059571

IF: 3.006

2022-06-21

BMJ Open

Abstract:Introduction The prevalence of eye diseases has been increasing worldwide. In China, in addition to conventional medicine, Traditional Chinese Medicine (TCM) plays an important role in maintaining people's vision health. Although less flexible and targeted than TCM decoction, Chinese Patent Medicines (CPMs) are stable and well used. In recent years, CPMs have been increasingly used in ophthalmology clinics by TCM practitioners and by Western doctors in general hospitals. However, comprehensive evidence for using CPMs in ophthalmology is lacking. Aim We will apply the methodology of scoping review to systematically search and sort out the available evidence on oral CPMs for the treatment of eye diseases, identify the distribution of evidence in this field and provide a basis for clinical practice and medical decisions. Methods The scoping review will be implemented in the following seven steps: (1) defining the research question; (2) searching National Essential Medicines List (2018 edition ), National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020 edition ) and Chinese Pharmacopoeia (2020 edition ) for oral CPMs for the treatment of eye diseases; (3) searching Embase, Web of Science, PubMed, Cochrane Library, Chongqing VIP Chinese Scientific Journals Database, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database and Wanfang Database for relevant literature published from inception to December 2021; (4) developing eligibility criteria; (5) screening the studies based on inclusion criteria; (6) extracting relevant data and lastly, (7) collating, summarising and reporting the results. Ethics and dissemination Since the scoping review aims at collecting data from publicly available publications, this study does not require ethical approval. The results will be published in a peer-reviewed journal and presented at scientific conferences.

medicine, general & internal
Expert Consensus on Key Issues of Quality Control in Clinical Trials of New Drugs of Traditional Chinese Medicine

Wei-An Yuan,Jian-Yuan Tang,Rui Gao,Si-Yuan Hu,Yan-Ling Zhao,Chong Zou,Bo Li,Jun-Hua Zhang,Lei Zhang,Zhong-Qi Yang

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20210219.501

2021-01-01

Abstract:Since "the implementation of good clinical practice"(GCP), especially after 2015, the overall quality of new drug cli-nical trials in China has made significant progress, but compared with developed countries, there are still some obvious quality problems in clinical trials in China. Clinical trials of new drugs of traditional Chinese medicine are an important part of clinical trials of new drugs in China. In addition to some common problems in all clinical trials, there are also some special quality problems. In terms of security data, such as the collection of human safety data is not standardized, the management and judgment of unexpected serious adverse reactions(SUSAR) were not professional and timely, the relationship between adverse events and trial drug was not fully judged by investigator, In terms of effective data, such as primary efficacy outcome of the scale cannot be traced, TCM syndrome data cannot meet the requirements of "source data" in the revised GCP and the quality of traditional Chinese medicine placebo is not high, in terms of overall quality system construction, the sponsors and research institutions have not established a quality assurance system that conforms to the characteristics of new drug research of traditional Chinese medicine, etc. The quality of clinical trials of new drugs of traditional Chinese medicine is based on the current GCP and ICH-GCP in China, we should also consider the characteristics of clinical trials of new traditional Chinese medicine drugs, and formulate targeted quality control measures according to the characteristics of these new drugs of traditional Chinese medicine, to improve the overall quality of clinical trials of new drugs of traditional Chinese medicine in China, which has important strategic significance for promoting the research and development of new drugs of traditional Chinese medicine in China.
'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors

Nan Zhang,Changming Zhong,Guoxiu Liu,Siyu Li,Li Lin,Namin Wei,Yu Song,Xiaoqing Wan,Yanping Wang,Yongyan Wang,Wanlin Wu,Zhongzhi Qian,Huaqiang Zhai

DOI: https://doi.org/10.3389/fphar.2024.1324509

2024-08-23

Abstract:Background: Chinese patent medicines are specialty preparations in China that are produced using traditional prescriptions processed by modern pharmaceutical technology. They contain complex ingredients and much attention is paid to their clinical safety. Demonstrating the clinical safety of Chinese patent medicines containing toxic ingredients in modern pharmacological studies has become one of the urgent issues to be solved for the safe use of clinical medicines. Objectives: The aim of this research is to evaluate the safety of Chinese patent medicines containing toxic ingredients by applying the risk-benefit assessment method. Additionally, a database of 'toxic ingredients-toxic Chinese herbal medicines-adverse reactions' will be established to explore the relationship between toxic ingredients and adverse reactions. This will lay the foundation for the rational clinical use of Chinese patent medicines containing toxic ingredients. Methods: 1) Establish a database of 'toxic Chinese herbal medicines-toxic ingredients-toxic Chinese patent medicines' to count the Chinese patent medicines containing toxic ingredients in the 2020 edition of Chinese Pharmacopoeia. 2) Filtered the clinical studies, extracted the drug-related ADEs, and analyzed the characteristics and correlations of these ADEs. 3) Finally, this section summarizes the causes of ADEs related to Chinese patent medicines containing toxic ingredients and extracts the main risk factors to provide a reference for further study. Outcomes: 1) There are four main types of Chinese patent medicines containing toxic ingredients. These include medicines with diester aconitine metabolites, mineral composition, Araceae metabolites, and hydrogen cyanide. 2) Digestive system, skin and its appendages, and allergic reactions were the main types of ADEs related to four types of Chinese patent medicines containing toxic ingredients. 3) There are four primary risk factors associated with the clinical use of Chinese patent medicines containing toxic ingredients: medicine, medication, individual and regulatory factors.
[Guidelines for Economic Evaluation of Post-Marketing Chinese Patent Medicine].

Lu-Wen Shi,Yan-Ming Xie,Xiao-Yan Nie,Sheng Han,Xia Tian,Zhi-Fei Wang

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20231018.501

2024-01-01

Abstract:With the premise of drug safety and effectiveness, pharmacoeconomic evaluation can provide optimal solutions for diversified decision-making application scenarios from different research perspectives while maximizing the rational utilization of existing healthcare resources. Chinese patent medicine is an essential component of pharmaceutical utilization in China and a significant part of healthcare expenditure in China. However, the economic evaluation of post-marketing Chinese patent medicine is lacking. These evaluations often lack standardization, exhibit varying quality, and are unable to effectively support healthcare decisions, indicating a need for improvement in overall quality. Given this situation, this project has gathered leading experts from China and has strictly adhered to the requirements of the group standards set by the China Association of Traditional Chinese Medicine in developing Guidelines for economic evaluation of post-marketing Chinese patent medicine, aiming to provide methodological guidance for the post-market pharmacoeconomic evaluation of Chinese patent medicine, enhancing the standardization of pharmacoeconomic evaluations of Chinese patent medicine and the scientific validity of research results, and thereby elevating the overall quality of pharmacoeconomic evaluations for post-marketing Chinese patent medicine. The guidelines adhere to the framework provided by relevant laws and regulations in China and technical guidance documents. It is based on guidance from traditional Chinese medicine(TCM) theories, focusing on the unique characteristics of TCM. It covers various aspects of pharmacoeconomic evaluation, including fundamental principles, research topic selection, research question definition, study design type selection, cost identification and measurement, health outcomes, and evaluation methods. The guidelines offer methodological recommendations and decision guidance to address common issues and challenges in the pharmacoeconomic evaluation of post-marketing Chinese patent medicine.

Occupational coal tar dermatitis

[Pharmacovigilance guidelines of Chinese patent medicines]

[Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines]

[Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use]

[Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions]

Beyond freedom and dignity at 40: Comments on behavioral science, the future, and chance (2007)

Notice for Western Medicine Physicians in Clinical Use of Chinese Patent Drugs

Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine

[Report standards for clinical comprehensive evaluation of Chinese patent medicine]

An Intelligent Information Dictionary for Semantic Manipulation of Relational Databases

Clinical practice guidelines of Chinese patent medicine in China: A critical review

Recent advances in Chinese patent medicines entering the international market

Answer to case of the month #136. Endometrioma of the rectus sheath after Caesarean section.

[On the possibilities of prevention of afibrinogenemic hemorrhages].

Pharmacovigilance in China: A review

Guideline on treating community-acquired pneumonia with Chinese patent medicines

Pharmacovigilance in China: Evolution and future challenges.

Clinical application of oral Chinese Patent Medicines in ophthalmology: a scoping review protocol

Expert Consensus on Key Issues of Quality Control in Clinical Trials of New Drugs of Traditional Chinese Medicine

'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors

[Guidelines for Economic Evaluation of Post-Marketing Chinese Patent Medicine].